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Abstract
Background: Disturbances in the early establishment of the intestinal microbiota may produce important implications
for the infant’s health and for the risk of disease later on. Different perinatal conditions may be affecting the development
of the gut microbiota. Some of them, such as delivery mode or feeding habits, have been extensively assessed whereas
others remain to be studied, being critical to identify their impact on the microbiota and, if any, to minimize it. Antibiotics
are among the drugs most frequently used in early life, the use of intrapartum antimicrobial prophylaxis (IAP), present in
over 30% of deliveries, being the most frequent source of exposure. However, our knowledge on the effects of IAP on the
microbiota establishment is still limited. The aim of the present work was to evaluate the impact of IAP investigating a
cohort of 40 full-term vaginally delivered infants born after an uncomplicated pregnancy, 18 of which were born from
mothers receiving IAP.
Results: Fecal samples were collected at 2, 10, 30, and 90 days of age. We analyzed the composition of the fecal
microbiota during the first 3 months of life by 16S rRNA gene sequencing and quantified fecal short chain fatty acids by
gas chromatography. The presence of genes for resistance to antibiotics was determined by PCR in the samples from
1-month-old infants. Our results showed an altered pattern of intestinal microbiota establishment in IAP infants during the
first weeks of life, with lower relative proportions of Actinobacteria and Bacteroidetes and increased of Preoteobacteria and
Firmicutes. A delay in the increase on the levels of acetate was observed in IAP infants. The analyses of specific antibiotic
resistance genes showed a higher occurrence of some β-lactamase coding genes in infants whose mothers received IAP.
Conclusions: Our results indicate an effect of IAP on the establishing early microbiota during the first months of life, which
represent a key moment for the development of the microbiota-induced host homeostasis. Understanding the impact of
IAP in the gut microbiota development is essential for developing treatments to minimize it, favoring a proper gut
microbiota development in IAP-exposed neonates.
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Background
The human gut harbors a rich and complex microbiota
whose establishment begins in early life. This microbiota
contributes to an appropriate gut development and intes-
tinal barrier function, resulting essential for the metabolic
and immune homeostasis of the host [1, 2]. During the last
years, an increasing amount of scientific evidence has
underlined the important role of the early-life gut micro-
biota establishment and the development of such micro-
biota, in the later health of the individual [2–6]. This early
microbiota-host interaction affects not just the local gut en-
vironment but also distal organs [7, 8]. Therefore, any dis-
turbance on the intestinal microbiota development process
in these early moments may have important implications
for the infant’s health and also for the risk of disease later
on life. Indeed, an aberrant early microbiota has been
found to precede the development of diseases [9–11].
Traditionally, infants have been considered sterile in
utero, but recent data support the occurrence of a cer-
tain degree of microbial exposure prior to delivery [12].
At birth, the microbial exposure becomes massive and
the newborn is rapidly and densely populated by a com-
plex microbiota. This microbial colonization begins with
facultative anaerobic and aerotolerant microorganisms
which reduce the intestinal environment allowing the
further establishment of strict anaerobes, such as Bifido-
bacterium and Bacteroides [13, 14]. After the initial
colonization steps, the infant microbiota often appears
dominated by Actinobacteria, frequently accompanied
also by high levels of Proteobacteria [15–17]. This intes-
tinal colonization process is going to be dependent on
both genetic and environmental factors [18]. Among the
last ones, many different prenatal and postnatal condi-
tions may be affecting the colonization process, includ-
ing gestational age at birth, mode of delivery, use of
antibiotics, or feeding habits [17–21]. Some of these fac-
tors, such as being born by C-section or receiving antibi-
otics, have been associated with an increase in the risk
of later disease [22].
Antibiotics are among the drugs most frequently used
in early life. During the last years, different animal stud-
ies have demonstrated that reduced exposure to mi-
crobes early in life is associated with an increased risk of
later disease [11, 23]. Moreover, antibiotics-induced
microbiota dysbiosis in early life leads to increased suscepti-
bility to allergic and metabolic disorders [24–26]. The most
frequent cause of exposure to antibiotics during the peri-
natal period is the use of intrapartum antimicrobial prophy-
laxis (IAP), which is present in over 30% of deliveries [27].
Several studies have shown that early postnatal antibiotic ex-
posure disturbs the natural establishment of the intestinal
microbiota in the newborn with potential negative influ-
ence in later health [28, 29]. However, with the exception
of some preliminary culture-based assessment [30], only
recently studies focusing on the impact of IAP on the
microbiota development, in both preterm and full-term
newborns, have started to be available [17, 31–33]. In spite
of this, our knowledge on the effects of IAP on the intes-
tinal microbiota development is still limited.
The aim of the present study was to evaluate the im-
pact of IAP on the establishment of the gut microbiota
in the newborn. To avoid the presence of potential con-
founders, we focused on vaginally delivered full-term in-
fants remaining healthy during the length of the study.
To this end, we used 16S rRNA gene sequence-based
fecal microbiota analysis, gas chromatography (GC) for
quantification of fecal short chain fatty acids (SCFAs) as
a measure of microbiota metabolic activity, and PCR for
the detection of specific antibiotic resistance genes.
Methods
Study participants
The study was approved by the Regional Ethical Committee
of Asturias Public Health Service (SESPA), and an informed
written consent was obtained from each infant’s parents. The
study included 40 full-term (gestational ages >37 weeks) vagi-
nally delivered infants born after an uncomplicated preg-
nancy at the Central University Hospital of Asturias
(Northern Spain). Eighteen of the mothers received intrapar-
tum antimicrobial prophylaxis (in all cases, an initial dose of
5 million units of penicillin followed by 2.5 million units
every 4 h until delivery; in most cases, the mothers received
three or less doses), due to confirmed or suspected vaginal
colonization by group-B-streptococci (IAP group); whilst,
the other 22 mothers, all of them being culture negative
for group-B-streptococci, were not exposed to antibiotics
(no-IAP group). None of the mothers received antibiotics
during pregnancy or the postnatal period, other than the
above mentioned IAP, and none of the infants received
antibiotics during the duration of the study. Eighteen
infants from the no-IAP and 11 from the IAP group were
exclusively breast-fed during the study period whilst the
remaining newborns (four in the no-IAP and seven in IAP
group; difference no statistically significant) received
infant formula milk. All infants were discharged from the
hospital after 2 or 3 days of life.
Sample collection
Fecal samples were collected at 2, 10, 30, and 90 days of
age. A fresh fecal sample was taken in a sterile container
by the parents and immediately frozen at −20 °C. Sam-
ples were sent within 1 week to the laboratory where
they were stored at −80 °C until DNA extraction.
Fecal DNA extraction
Fecal samples were thawed, weighed, diluted 1/10 in
sterile PBS solution, homogenized in a LabBlender 400
stomacher for 5 min, and DNA was extracted using the
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QIAamp DNA stool kit (Qiagen GmbH, Hilden,
Germany) as previously described [14]. Extracted DNA
was kept frozen at −80 °C until analysis.
16S rRNA gene sequence-based microbiota analysis
Partial 16S rRNA gene sequences were amplified from ex-
tracted DNA using primer pair Probio_Uni and /Pro-
bio_Rev, which target the V3 region of the 16S rRNA gene
sequence [34]. 16S rRNA gene sequencing was performed
using a MiSeq (Illumina) according to the protocol previ-
ously reported [34]. Following sequencing, the obtained in-
dividual sequence reads were filtered by the Illumina
software to remove low quality sequences. All Illumina
quality-approved, trimmed, and filtered data were exported
as .fastq files. The .fastq files were processed using a cus-
tom bash script based on the QIIME software suite [35].
This script performs a quality control of the sequences and
retains only those with a length between 140 and 400 bp
as well as mean sequence quality score >20, truncates se-
quences at the first base if a low quality rolling 10 bp win-
dow was found, and removes reads with homopolymers
>7 bp as well as with mismatched primers. The custom
bash script then integrates Qiime python scripts in order
to generate de novo 16S rRNA Operational Taxonomic
Units (OTUs) with ≥97% identity using uclust [36], remove
OTUs with less than 10 sequences, pick a random
reference sequence for each OTUs, classify OTUs down to
the genus level by means of the SILVA database v.123 [37],
remove chimeric sequences using ChimeraSlayer (http://
microbiomeutil.sourceforge.net/), and calculate alpha-
diversity rarefaction curves using chao1, Shannon, and
observed number of OTUs indices.
SCFAs analysis
The concentration of SCFAs in feces (mM) was deter-
mined in a chromatographic system composed of two
6890 N GC (Agilent Technologies Inc., Palo Alto, CA,
USA) connected to a FID and a MS 5973N detector as
previously described [38].
Detection of antibiotic resistance genes in fecal samples
The occurrence of different antibiotic resistance genes in
fecal samples from 1-month-old infants was determined
by PCR (UnoCycler, VWR International, Pennsylvania,
USA) using previously described primers (Table 1). All
oligonucleotides were purchased from Macrogen Europe
(Macrogen, Amsterdam, The Netherlands). PCRs were
performed in a total volume of 25 μl containing 1 μl of
fecal DNA extract as a template. The reaction mixture
was composed of 1× Dream PCR Master Mix (Thermo
Fischer Scientific, San Jose, CA, USA) using 0.2 μM of
each primer. The thermal cycle program consisted of the
following time and temperature profile: an initial cycle
of 94 °C for 5 min, 35 cycles of 30 s at 94 °C, 30 s at the
annealing temperature of the corresponding primer pair
(Table 1) and 1 min at 72 °C, and a final extension step
of 7 min at 72 °C. Amplified products were subjected to
gel electrophoresis in 1% agarose gels and were visual-
ized by ethidium bromide staining.
Statistical analyses
Results were analyzed using the SPSS software (SPSS Inc.
Chicago, USA). The normality of the data, at each sam-
pling point, was checked, and some of the bacterial groups
showed non-normal distribution; therefore, differences
Table 1 Primers and annealing temperatures used for the detection of antibiotic resistance genes by PCR
Gene Oligonucleotide Annealing
T°
Antibiotic group Resistance mechanisms Ref.
tet(W) F-AAGCGGCAGTCACTTCCTTCCR-
TCAAGTATCCCAGCGAAACC
60 Tetracyclines Ribosomal Protection Protein [49]
tet(M) F-ACAGAAAGCTTATTATATAACR-
TGGCGTGTCTATGATGTTCAC
55 Tetracyclines Ribosomal Protection Protein [49]
tet(O) F-ACGGARAGTTTATTGTATACCR-
TGGCGTATCTATAATGTTGAC
60 Tetracyclines Ribosomal Protection Protein [49]
tetA(B) F-TTGGTTAGGGGCAAGTTTTGR-GTAATGGGCCAATAACACCG 55 Tetracyclines Efflux pump [63]
blatem F-TTTCGTGTCGCCCTTATTCCR-CCGGCTCCAGATTTATCAGC 60 Penicillins β-lactamase [63]
blaCTX-M F-ATGTGCAGYACCAGTAARGTKATGGCR-
GGGTRAARTARGTSACCAGAAYSAGCGG
60 Penicillins β-lactamase [50]
blaSHV F-CACTCAAGGATGTATTGTGR-TTAGCGTTGCCAGTGCTCG 58 Penicillins β-lactamase [64]
mecA F-GGGATCATAGCGTCATTATTCR-
AACGATTGTGACACGATAGCC
56 Penicillins Penicillin-binding protein 2a [50]
aac(6″)-Ie-
aph(2″)
F-CCAAGAGCAATAAGGGCATACCR-
CACACTATCATAACCATCACCG
55 Aminoglycosides Bifunctional acetyltransferase
phosphotransferase
[64]
strA F-CTTGGTGATAACGGCAATTCR-CCAATCGCAGATAGAAGGC 65 Aminoglycosides Phosphotransferase [63]
cmlA1 F-CACCAATCATGACCAAGR-GGCATCACTCGGCATGGACATG 60 Chloramphenicol Efflux pump [63]
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between groups of infants were analyzed using non-
parametric tests (Mann-Whitney U test or Kruskal-Wallis
test). Pearson χ2 test and logistic regression were used for
assessing the occurrence of the different antibiotic resist-
ance genes analyzed in both groups.
Nucleotide sequence accession numbers
The raw sequences reported in this article have been de-
posited in the NCBI Short Read Archive (SRA) under
accession number PRJNA362530.
Results
Impact of IAP on the intestinal microbiota composition of
the newborn
Sequencing of the PCR products obtained by amplification of
the V3-V4 region of the 16S rRNA gene from the samples
analyzed yielded an average of ~60,000 filtered partial se-
quences per sample with an average length of 178 bp. A
minimum of 47,000 sequences per sample were used for
standardizing the microbiota measures. Rarefaction curves in-
dicated that the sequencing depth was enough since the sam-
ples reached the plateau phase (Additional file 1: Figure S1).
IAP was found to reduce alpha-diversity in comparison with
no-IAP infants (Additional file 2: Figure S2).
The microbiota of our full-term vaginally delivered in-
fants was initially (2 days of age) dominated by Proteo-
bacteria which represented a relative proportion of 67%
in infants from mothers receiving IAP and of 50% in
non-IAP-exposed infants (Fig. 1). The levels of this bac-
terial phylum decreased along time reaching levels of
46% in IAP-exposed and 35% in non-exposed infants at
10 days of age. These levels were further reduced to 36
and 27%, respectively, at 1 month of age and 34 and 32%
at the age of 3 months. In spite of these general lower
levels of Proteobacteria in non-IAP-exposed babies,
compared with infants from IAP-receiving mothers, the
differences did not reach statistical significance
(p > 0.05), likely due to the high inter-individual vari-
ation. The level of Firmicutes in IAP infants increased
from an initial 24% at 2 days of age to a 38% at 10 days,
the levels remaining stable afterwards. In contrast, the
levels of this microbial phylum did not show this in-
crease and were maintained constant in the control
group (infants not exposed to IAP), with only minor var-
iations along time (Fig. 1). This different behavior of Fir-
micutes in IAP vs. control infants resulted in
significantly higher levels (p < 0.05) of this phylum in
the former group at 10 and 90 days of age. On the con-
trary to that observed for Proteobacteria and Firmicutes,
the relative proportions of Actinobacteria, Bacteroidetes,
and others were higher in control than in IAP-exposed
infants (Fig. 1). These differences reached statistical sig-
nificance at 10 days of age for Actinobacteria.
Analyses of the data at family level confirmed these
differences, with some families showing statistically sig-
nificant changes related to the use of IAP (Additional file
3: Table S1). Among these, it is important to underline
the significantly lower levels of Bifidobacteriaceae and
unclassified Actinobacteria (p < 0.05) found in IAP in-
fants. On the contrary, the latter group of infants pre-
sented increased levels (p < 0.05) of Prevotellaceae at 2
and 90 days of age, Rikenellaceae at 2 days of age, Clos-
tridiaceae at 10 days of age, and of Campylobacteriaceae
and Helicobacteriaceae at the end of the study
(3 months). Moreover, the levels of the group classified
as Family S24–7 (Muribaculaceae), a Bacteroidetes
group commonly found in feces from homoeothermic
animals [39], but whose first cultured representative
remained elusive till recently [40], were significantly in-
creased in IAP infants all along the study.
Impact of IAP on the intestinal production of SCFAs in the
infant gut
The levels of the main fecal SCFAs (acetate, propionate,
and butyrate) increased over time in both infant groups.
Infants whose mothers received IAP showed a trend to-
wards lower levels of propionate and acetate during the
first days of life (Fig. 2). These differences were statistically
Fig. 1 Relative proportions (%) of the main bacterial phyla present
in the fecal samples obtained from both infant groups, newborns
whose mothers received IAP (black columns) and those whose
mothers dis not (white columns), at the different sampling points.
Asterisk indicates statistically significant differences (p < 0.05)
between both groups of infants
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significant (p < 0.05) for propionate at 2 days of life, when
the levels of these SCFAs in infants not exposed to IAP al-
most doubled those in IAP infants (5.3 vs 3.1 mM, re-
spectively). However, likely due to the high inter-
individual variability observed in the levels of fecal SCFAs,
no other statistically significant differences were obtained.
This apparent delay in the production of acetate and pro-
pionate during the first days of life disappeared already at
30 days of age, when the levels of SCFAs in IAP infants
were even slightly higher (p > 0.05) than in the control in-
fants, and remained mostly unchanged during the rest of
the study. When the SCFAs were calculated as relative
proportions (percentage with regard to the total SCFAs
level), no statistically significant differences were observed
at any time point analyzed (Additional file 4: Figure S3).
Effect of feeding habits on the impact of IAP upon the
infant intestinal microbiota composition
To assess the potential influence of the infant feeding
habits upon the observed effects of IAP on the establish-
ing infant gut microbiota, we compared the data ob-
tained for the exclusively breast-fed babies with those
for formula-fed ones, both in mothers receiving and not
receiving IAP. The results showed differences in the
microbiota depending on the infant feeding habits as
well as differential responses to IAP between both infant
groups (Additional file 5: Table S2). Exclusively breast-
fed infants not exposed to IAP showed higher levels of
Bacteroidetes all along the study and lower early levels
of Proteobacteria than unexposed formula-fed ones.
Interestingly, regardless of IAP exposure, lower levels of
Actinobacteria were observed in formula-fed newborns
during early days life, but this trend changed afterwards
with formula-fed infants showing higher levels after
1 month of age. Similarly, Verrucomicrobia levels were
higher in the formula-fed group at the end of the study
(90 days of age).
Regarding the response to IAP, antibiotics exposure re-
duced the levels of Actinobacteria and increased those of
Firmicutes, and to a lesser extent Proteobacteria, in both
breast and formula-fed infants (Additional file 5: Table S2).
In the case of Bacteroidetes the response to IAP was variable
depending on the infant feeding pattern; thus whereas IAP
reduced the levels of this phylum in exclusively breast-fed
infants, the contrary was true in formula-fed ones. To fur-
ther delineate this differential behavior, the relationship be-
tween non-IAP and IAP group was calculated for the
different microorganisms in both breast-fed and formula-fed
infants (Fig. 3). As expected from the composition data, the
levels of Proteobacteria and Firmicutes were higher in IAP-
exposed infants rendering a low ratio. This was true for both
breast- and formula-fed infants. However, in the case of
Actinobacteria and to a larger extent of Bacteroidetes, the
impact of IAP seems to be different between breast-fed and
formula-fed babies (Fig. 3). This is especially true for Bacter-
oidetes since all the main representative families of this
phylum (Bacteroidaceae, Prophyromonadaceae, and Prevo-
tellaceae) showed a lower ratio between non-IAP and IAP
babies in the case of the formula-fed newborns (Fig. 3).
Similar results were also obtained for the families P5D1-392,
including unculturable microorganism from the Lactobacil-
lales order, Lachnospiraceae, Ruminococcaceae, or Acidami-
nococcaceae, among others (Fig. 3).
Impact of IAP on the carriage of antibiotic resistance
genes
The assessment of the occurrence of different antibiotic
resistance genes in the feces of 1-month-old infants by
Fig. 2 Concentration (mM) of acetate, propionate, and butyrate and total SCFAs in feces from infants whose mothers received IAP (IAP; n = 18)
and those whose mothers did not (noIAP; n = 22)
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PCR with specific primer pairs showed variability among
the analyzed genes (Table 2). Whilst, the genes tetM,
tetO, tetA, strA, or clmA1 were not detected in any sam-
ple; others such as BLA-tem, mecA, or CTX-M resulted
positive in more than 30% of the infants. Interestingly,
the β-lactamase genes BLA-tem, CTX-M, and the gene
acc6-aph2, conferring resistance to aminoglycosides,
showed an increased occurrence in infants from IAP-
receiving mothers than in non-antibiotic exposed ones
(Table 2). However, these differences did not reach statistical
significance (p > 0.05); although in the case of BLA-tem, a
trend towards increased occurrence seems to be present
(χ2; 0.05 < p < 0.01), which is in agreement with the logistic
regression analyses that also suggest IAP as a predictor of
the occurrence of this gene (Odds ratio 4.3; p < 0.1).
Discussion
During the last decade, we have started to understand
the critical role of the early-life microbiota-host inter-
action as a determinant of later health [2, 41]. To this re-
gard, the use of antibiotics may influence gut microbiota
composition with consequences for later health [42].
Moreover, incomplete microbiota recovery after antibi-
otics administration, in both adults and infants, has been
observed [43, 44]. These results point out to the need of
Fig. 3 Ratio obtained for the different microbial phyla (a) and families (b) between no-IAP exposed infants (babies whose mothers did not receive
IAP) and IAP-exposed ones in exclusively breast-fed infants (n = 29, 10 no-IAP and 11 IAP) and in formula-fed ones (n = 11, 2 no-IAP and 7 IAP).
The ratio was calculated as relative proportion in no-IAP/relative proportion in IAP newborns at the different time points analyzed
Table 2 Occurrence (% of positive samples) of the different
antibiotic resistance genes analyzed, in fecal samples from
1-month-old infants from mothers receiving IAP (n = 18)
and those from mothers that did not receive intrapartum
antibiotics (n = 22)
Group Antibiotic resistance genea
tetW BLA-tem mecA CTX-M BLA-shv acc6-aph2
No-IAP 9.0% 61.9% 57.1% 33.3% 14.3% 23.8%
IAP 7.7% 82.3% 44.4% 52.9% 11.1% 38.9%
aNone of the samples was positive for tetM, tetO, tetA, strA, or cmlA1
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defining and understanding the factors, such as IAP,
which may determine the initial establishment of the gut
microbiota.
In general, the composition of the gut microbiota in our
study is similar to that reported by other authors in other
full-term vaginally delivered baby cohorts [17, 32, 34, 44,
45]. As it is common in this typology of studies, a large
inter-individual variability was observed, which hampers
the statistical analyses of the results. Despite this large
variability, our results demonstrate the impact of maternal
IAP upon the composition of the gut microbiota in the in-
fant during the first months of life. Similarly to other re-
cent 16S rRNA gene-based studies, carried out in both
preterm and full-term infants [17, 31–33], we observed a
reduction on the levels of Actinobacteria and Bacteroi-
detes and an increase of Proteobacteria and Firmicutes in
babies from mothers receiving IAP than in those not ex-
posed to antibiotics. To note, infants in the IAP group
showed reduced proportions of commensal microorgan-
isms, such as the family Bifidobacteriaceae, but increased
of potentially pathogenic microorganisms including Cam-
pylobacteriaceae or Helicobacteriaceae. Some of these dif-
ferences were only present during a certain time,
disappearing afterwards. For instance, infants whose
mothers received IAP showed lower relative proportions
of Bifidobacteriaceae at 10 days of age but not at the age
of 1 month, which is in good agreement with the results
obtained by Corvaglia and coworkers [46] by using qPCR
for the genus Bifidobacterium. Moreover, our results indi-
cate that some IAP-induced microbiota alterations remain
for up to 3 months of age. To this regard, Mazzola and co-
workers [33] recently reported similar differences to those
obtained by us, persisting up to 1 month of age, which
was the duration of their study. Similar to our results,
Azad et al. [32] have also recently reported reduced levels
of Bacteroidetes and increased of Proteobacteria in 3-
month-old vaginally delivered infants whose mothers re-
ceived IAP, these differences disappearing by the age of
1 year. Moreover, a similar pattern with increased
colonization by potentially pathogenic enterobacteria has
also been observed in preterm babies [17]. A question that
remains open is the exact mechanism behind the observed
effects. The spectrum of action of the antibiotic used,
penicillin, may partially explain the observed results since
it has a strong activity against gram-positive microorgan-
isms and by reducing them would allow the overgrowth of
gram-negatives such as Proteobacteria. However, this can
be more complex and depend on the specific spectrum
since Firmicutes (gram-positive) also show higher levels in
IAP infants whilst the levels of other gram-negative mi-
croorganisms, such as those from the phyla Bacteroidetes,
are reduced.
The information available on the impact of antibiotic
exposure in SCFA production during early life is very
scarce. Antibiotic use had been suggested as a potential
cause for low fecal SCFA levels [47], and we recently re-
ported lower levels of fecal SCFAs, especially of acetate,
in preterm infants exposed to antibiotics [38]. In the
same way, in the present study, we observed a trend to-
wards a delayed increase of fecal acetate levels in infants
from mothers receiving IAP in comparison with babies
not exposed to antibiotics. Given the important roles
that the SCFAs play in human physiology [48], this re-
duced acetate level during the first month of life could
have potential effects on infant development and health.
Our results suggest a potential interaction between IAP
administration and infant feeding habit. This is especially
relevant for the phylum Bacteroidetes whose levels were
much lower in formula-fed than in exclusively breast-fed
infants. These differences seem to affect the response to
IAP that differs between both groups of infants, giving an
extra complexity to the understanding of the effects of
early-life factors upon the microbiota. To this regard, Maz-
zola and coworkers [33] recently reported larger effects of
IAP in the microbiota of exclusively breast-fed babies than
in infants under mixed feeding. On the contrary, other au-
thors found a potential protective role of breast-feeding
against the IAP-induced microbiota changes in C-section-
delivered babies [32]. Different methodological issues such
as the limited number of newborns included in these stud-
ies, the several potentially confounding factors involved, as
well as the challenge of defining infant-feeding regime other
than exclusive breast-feeding, have difficulty in drawing
firm conclusions. To this regard, our results point out to a
differential response to IAP depending on infant feeding
which adds more difficulty for reaching general conclusions
or making recommendations. However, it would be import-
ant to define whether or not a protective role of breast-
feeding is actually present since this would provide a ration-
ale for additional efforts to encourage breast-feeding in
those cases in which IAP has been used.
Another interesting issue related to the early microbiota
composition that has remained largely unexplored is the
carriage of antibiotic resistance genes. The increase of mul-
tidrug resistant microorganisms is an important concern of
public health authorities worldwide. Given the potential
role of the gut microbiota as reservoir for antibiotic resist-
ance genes, the early microbiota establishment may also
constitute a critical step from this perspective. Some studies
have reported the presence of antibiotic resistance genes in
the early life microbiota [49, 50]. Gosalbes and co-workers
[50] demonstrated the presence of genes conferring resist-
ance to β-lactam antibiotics and tetracycline in the meco-
nium of more than half of the newborns. Moreover, the
results of these authors suggest the vertical mother-infant
transmission of antibiotic resistance genes and underline
the potential role of the infant microbiome as a reservoir of
resistance genes [50]. Gibson et al. [51] recently reported
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the enrichment of specific antibiotic genes following anti-
biotic treatments in preterm infants. However, although
IAP is a fairly common practice and the most frequent
cause of antibiotics exposure to antibiotics in neonates, no
study has addressed, until now, the possible impact of this
practice on the carriage of antibiotic resistance genes by the
infant microbiota. In the present study, we have focused on
genes previously reported to be relatively common in in-
fants [49–51] and observed an increased number of infants
harboring genes, such as BLA-tem, conferring resistance to
the antibiotics used in IAP (β-lactam) in the group of new-
borns whose mothers received IAP. On the contrary, no
differences between infants from others receiving and not
receiving IAP were observed for genes conferring resistance
to antibiotics that are not used in IAP, such as tetracycline.
Although the results did not reach statistical significance,
likely due to the limited sample size, the observed trend to-
wards an increased carriage of BLA-tem following IAP, with
an additional 20% of infants harboring the gene, deserves
further attention and confirmation in larger studies.
Our results, together with those recently reported by
other authors, indicate an effect of IAP on the establish-
ing early microbiota. Interestingly, this effect seems to
remain for at least the first months of life which repre-
sent a very critical time for the correct development of
the microbiota-induced host homeostasis [2, 41]. The
use of IAP is not a clear-cut decision [52] and is usually
recommended in cases in which prenatal screening dem-
onstrates colonization by group B streptococci [53]. Un-
fortunately, IAP is often also administered in cases in
which there is not a clear benefit [54, 55] and there is a
high rate of administration of inadequate IAP [56]. In
general, inappropriate antibiotic use is frequent in the
pediatric population, which is a matter of concern [57].
Moreover, it is becoming increasingly evident that
antibiotic-induced perturbation in the early microbiota
may have profound consequences for later health. Differ-
ent animal studies have demonstrated that the alteration
of the early microbiota with antibiotics increases the risk
for autoimmune and metabolic diseases, also affecting
behavior [24, 25, 58–60]. Actually, repeated exposure to
β-lactam antibiotics during infancy has been related with
an increased weight in later life [61], and the intestinal
microbiome of infants has been repeatedly reported to
be affected by antibiotic use [21, 62]. All these data point
out at the urgent need to rationalize the use of antibi-
otics and to develop intervention strategies aimed at
minimizing the impact of early-life antibiotics exposure
on the intestinal microbiota development process.
Conclusions
This study underlines the effect of maternal IAP on the
process of establishment of the intestinal microbiota in
the newborn. The initial stages of development may
represent the window of opportunity for intestinal
microbiota modulation, either towards the establishment
of a healthy microbial profile or to an aberrant profile.
Thus, it is essential to understand how different peri-
natal factors, such as the use of IAP, may affect the gut
microbiota development in the infant and to develop, if
needed, treatments to minimize the impact on the
microbiota development of any early-life intervention.
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